Scilex Holding Company Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent
Scilex Holding Company (SCLX) had Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent of $41.82 million as of 2022-06-30, per its 10-Q filed 2022-08-12.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent · last filed 2022-08-12
- 2022-06-30: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent $41.82M.
| Period end | Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent |
|---|---|
| 2022-06-30 | $41.82M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |